Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of GSK plc. (“GSK” or th
Bear Of The Day: GSK PLC (GSK)
08:11am, Thursday, 06'th Feb 2025
Healthcare stock investors have been feeling rather sick about the potential changes the Trump Administration may bring.
GSK Reported Strong Earnings, So I Reiterate My Strong Buy
08:00am, Thursday, 06'th Feb 2025
GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab s
NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK
GSK prelims get City thumbs up as investment banks upgrade
06:54am, Thursday, 06'th Feb 2025
UBS has raised its target price for GSK PLC (LSE:GSK, NYSE:GSK) from £15.80 to £16, following a better-than-expected full-year earnings report and a focus on improving shareholder returns. The pharm
GSK Tech Ecosystem Profile - Digital Transformation Strategies and Innovation Programs
04:02am, Thursday, 06'th Feb 2025
The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. The report provides insights into GSK
Investor Alert: Robbins LLP Informs Stockholders of the GSK PLC Class Action
07:54pm, Wednesday, 05'th Feb 2025
SAN DIEGO , Feb. 5, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all purchasers of the American Depository Receipts ("ADRs") of GSK PLC (NYSE: GSK)
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against GSK plc ("GSK" or the "Company") (NYSE:GSK). Such investors are advised t
GSK plc. (GSK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
05:00pm, Wednesday, 05'th Feb 2025
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) investors concerning the Company's possible
Rosen Law Firm Urges GSK plc (NYSE: GSK) Investors with Large Losses to Contact the Firm for Information About Their Rights
04:17pm, Wednesday, 05'th Feb 2025
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of American Depositary Receipts (“ADRs”) of
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
Securities Fraud Investigation Into GSK plc. (GSK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R.
03:16pm, Wednesday, 05'th Feb 2025
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of GSK plc. (“GSK” or the “Company”) (NYSE: GSK) on behalf of investors concerning the Company's possi
GSK Stock Jumps on Long-Term Outlook Boost, $2.5B Share Buyback Plan
12:26pm, Wednesday, 05'th Feb 2025
GSK Plc's (GSK) U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a stock buyback on the back of optimism about sales of its new drugs.
GSK plc (GSK) Q4 2024 Earnings Call Transcript
11:52am, Wednesday, 05'th Feb 2025
GSK plc (NYSE:GSK ) Q4 2024 Earnings Conference Call February 5, 2025 5:45 AM ET Company Participants Dame Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer Julie Brown - C
NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK
